Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: GlobeNewswire
Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance expected in Q2 2025 WARREN, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced positive topline results from its pediatric study for Anaphylm™ (epinephrine) sublingual film in patients aged seven to seventeen and weighing greater that thirty kilograms with a personal history of allergic reactions. This marks the completion of the Anaphylm clinical program and supports the clinical data needed for the NDA submission. Aquestive has submitted the Anaphylm NDA to the U.S. Food and Drug Administration (FDA) and expects to receive potential acceptance of the NDA du
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Jim Cramer on Aquestive Therapeutics: “I Think It's a Very Interesting Spec” [Yahoo! Finance]Yahoo! Finance
- Looking at the Narrative for Aquestive Therapeutics After Patent Wins and FDA Milestones [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics, Inc. (NASDAQ:AQST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.10 [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics (NASDAQ:AQST) had its price target raised by analysts at Piper Sandler from $5.00 to $8.00. They now have an "overweight" rating on the stock.MarketBeat
AQST
Earnings
- 11/5/25 - Miss
AQST
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 4
- 11/17/25 - Form 144
- AQST's page on the SEC website